NR

Based on the available clinical trial evidence, nicotinamide riboside (NR) is being investigated for several therapeutic applications, though research remains in early phases.

Cardiovascular and Exercise Performance
The completed NEET Trial (NCT04112043) examined NR as an enhancer of exercise therapy in hypertensive older adults in a Phase 1 study. A separate completed trial (NCT04907110) investigated NR supplementation combined with exercise, though specific outcomes from these studies are not detailed in the available evidence.

Neurological Conditions
The most advanced application appears to be in neurodegeneration, with the ongoing NADAPT Study (NCT06162013) currently recruiting participants for a Phase 2 randomized, double-blind trial examining NAD replenishment therapy for atypical parkinsonism. This represents the highest phase trial identified for NR.

Sleep Disorders
A planned trial (NCT07284225) will examine acute effects of NR on sleep structure in healthy adults using polysomnography measurements, though this study has not yet begun recruiting.

Evidence Limitations
The clinical evidence for NR is notably limited. Only one Phase 2 trial was identified, with most investigations remaining in Phase 1 or observational stages. The completed trials lack published outcome data in the available evidence, making it difficult to assess clinical efficacy. The research spans diverse applications from cardiovascular health to neurodegeneration, but definitive therapeutic benefits have not been established based on the current evidence.

This information is for educational purposes only and should not replace professional medical advice. Consult with a healthcare provider before considering any supplementation.